Do We Need Maintenance With Anti-Cd20 Antibody After First-Line Therapy for All Newly Diagnosed Follicular Lymphoma Patients?

Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2018.06.073
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Management of Patients With Follicular Lymphoma Treated First Line With Obinutuzumab

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2019English

Phase I Study of Chimeric Anti-Cd20 Monoclonal Antibody in Chinese Patients With CD20-positive Non-Hodgkin’s Lymphoma

Chinese Journal of Cancer Research
Cancer ResearchOncology
2016English

M7‐FLIPI Is Not Prognostic in Follicular Lymphoma Patients With First‐line Rituximab Chemo‐free Therapy

British Journal of Haematology
Hematology
2019English

First-Line Therapy of CD20+ Diffuse Large B-Cell Lymphoma: Facts and Open Questions

Haematologica
Hematology
2009English

Do All Patients With Recurrent Ovarian Cancer Need Systemic Therapy?

Cancer
Cancer ResearchOncology
2019English

Secondary Antibody Deficiency: A Complication of Anti-Cd20 Therapy for Neuroinflammation

Journal of Neurology
Neurology
2018English

Pd-1 Immune Checkpoint Blockade Improves Anti-Cd20 Based Immunotherapy in Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Maintenance Rituximab or Observation After Frontline Treatment With Bendamustine-Rituximab for Follicular Lymphoma

British Journal of Haematology
Hematology
2018English

Noninvasive Phosphorus Magnetic Resonance Spectroscopic Imaging Predicts Outcome to First-Line Chemotherapy in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma

Academic Radiology
Nuclear MedicineRadiologyImaging
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy